Phentermine
Fastin, Ionamin, Obestin, Oby-trim, Ona-mast, Qsymia, Suprenza, Tora, Wilpo (phentermine) is a small molecule pharmaceutical. Phentermine was first approved as Fastin on 1982-01-01. It is used to treat obesity in the USA.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
Combinations
Qsymia
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| adipex-p | ANDA | 2020-09-30 |
| lomaira | ANDA | 2023-04-07 |
| phentermine hydrochloride | ANDA | 2023-06-16 |
| qsymia | New Drug Application | 2022-01-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| obesity | EFO_0001073 | D009765 | E66.9 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PHENTERMINE HYDROCHLORIDE / TOPIRAMATE, QSYMIA, VIVUS | |||
| 2025-06-24 | NPP | ||
HCPCS
No data
Clinical
Clinical Trials
54 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 2 | 6 | 5 | 12 | 5 | 30 |
| Bariatric surgery | D050110 | — | 2 | — | 1 | — | 3 | ||
| Weight loss | D015431 | HP_0001824 | — | 1 | — | 1 | 1 | 3 | |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | 1 | — | 2 |
| Morbid obesity | D009767 | EFO_0001074 | — | 1 | — | 1 | — | 2 | |
| Alcoholic fatty liver | D005235 | K70.0 | — | — | — | 1 | — | 1 | |
| Healthy lifestyle | D000070497 | — | — | — | 1 | — | 1 | ||
| Blood pressure | D001794 | EFO_0004325 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | 1 | — | — | 1 |
| Urinary calculi | D014545 | N20.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | 1 | — | — | — | 3 | ||
| Overweight | D050177 | E66.3 | — | 1 | — | — | 2 | 3 | |
| Pediatric obesity | D063766 | 1 | 2 | — | — | — | 3 | ||
| Binge-eating disorder | D056912 | F50.2 | 1 | 1 | — | — | — | 2 | |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | 1 | — | — | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | — | 1 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 1 | — | — | — | 1 |
| Drug therapy | D004358 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 3 | — | — | — | — | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
| Bulimia nervosa | D052018 | EFO_0005204 | F50.2 | 1 | — | — | — | — | 1 |
| Cocaine-related disorders | D019970 | F14 | 1 | — | — | — | — | 1 | |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | — | — | 2 | 2 |
| Hyperglycemia | D006943 | HP_0003074 | R73.9 | — | — | — | — | 2 | 2 |
| Critical illness | D016638 | — | — | — | — | 1 | 1 | ||
| Diet therapy | D004035 | — | — | — | — | 1 | 1 | ||
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | — | 1 | 1 |
| Enteral nutrition | D004750 | — | — | — | — | 1 | 1 | ||
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | — | 1 | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | — | 1 | 1 |
| Prostatic neoplasms | D011471 | C61 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PHENTERMINE |
| INN | phentermine |
| Description | Phentermine is a primary amine. It has a role as a dopaminergic agent, an adrenergic agent, a sympathomimetic agent, an appetite depressant, a central nervous system stimulant and a central nervous system drug. It is a conjugate base of a phentermine(1+). |
| Classification | Small molecule |
| Drug class | Appetite suppressant |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(N)Cc1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 122-09-8 |
| RxCUI | 8152 |
| ChEMBL ID | CHEMBL1574 |
| ChEBI ID | 8080 |
| PubChem CID | 4771 |
| DrugBank | DB00191 |
| UNII ID | C045TQL4WP (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Qsymia - Vivus
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,926 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,733 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more